Goldman Sachs questions whether curing patients is a sustainable business model
1–10 of 376 posts
Re: Goldman Sachs questions whether curing patients is a sustainable business model
#2Thats why "we the people" need to have large part in developing new drugs and the care of people, this is nothing that can be left to the "market" in some hope that it will "work out".
Re: Goldman Sachs questions whether curing patients is a sustainable business model
#3In this sense gene therapy is "disruptive innovation" in the Clayton M Christensen sense of the word: the incumbents cannot pursue the strategy as doing so eats into their profits. Does it take smaller, independent, outfits to pursue this?
Re: Goldman Sachs questions whether curing patients is a sustainable business model
#4A healthy person is bad for pharmaceutical business and doctors, yet very good for health and life insurances.
Re: Goldman Sachs questions whether curing patients is a sustainable business model
#5This is one of the downsides of mobbing, shaming and regulating away outrageous prices. If pharma companies can't charge you in the ballpark of a lifetime's earnings for a one-shot, one-shots will be less compelling to them compared with treatments you have to take twice a day for the rest of your life.
Re: Goldman Sachs questions whether curing patients is a sustainable business model
#6Thats why "we the people" need to have large part in developing new drugs and the care of people, this is nothing that can be left to the "market" in some hope that it will "work out".
Good idea, but it takes a lot of cash.
Re: Goldman Sachs questions whether curing patients is a sustainable business model
#7This is one of the downsides of mobbing, shaming and regulating away outrageous prices. If pharma companies can't charge you in the ballpark of a lifetime's earnings for a one-shot, one-shots will be less compelling to them compared with treatments you have to take twice a day for the rest of your life.
That assumes monopoly. Competition should solve that.
Re: Goldman Sachs questions whether curing patients is a sustainable business model
#8This is one of the downsides of mobbing, shaming and regulating away outrageous prices. If pharma companies can't charge you in the ballpark of a lifetime's earnings for a one-shot, one-shots will be less compelling to them compared with treatments you have to take twice a day for the rest of your life.
Or society could work differently, so that we try and cure people's diseases if we are able to.
Re: Goldman Sachs questions whether curing patients is a sustainable business model
#9This is one of the downsides of mobbing, shaming and regulating away outrageous prices. If pharma companies can't charge you in the ballpark of a lifetime's earnings for a one-shot, one-shots will be less compelling to them compared with treatments you have to take twice a day for the rest of your life.
That assumes monopoly. Competition should solve that.
Remembering basic human moral values might help as well.